Navigation Links
Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma therapy market will experience robust annual growth of more than 11 percent from 2012 to 2022 in the world's major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan). Immunotherapies will continue to dominate the malignant melanoma market through 2022. Sales for this drug class will increase dramatically during this period owing primarily to the anticipated launches of the immune checkpoint inhibitors, Bristol-Myers Squibb's nivolumab and Merck's MK-3475, for treatment of unresectable and metastatic melanoma and the anticipated adjuvant line-extension of Bristol-Myers Squibb's Yervoy. In 2022, sales of immunotherapies for melanoma will total more than $2.1 billion with sales of immune checkpoint inhibitors accounting for the vast majority of these sales.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor report entitled Malignant Melanoma finds that the BRAF/MEK inhibitor drug class will continue to play an important role in treatment of BRAF V600-mutation-positive unresectable and metastatic melanoma and that BRAF/MEK inhibitor combination therapy will become the preferred treatment approach over BRAF and MEK inhibitor monotherapy owing to its anticipated improved efficacy and safety and tolerability compared with monotherapy treatment. By 2022, three BRAF/MEK inhibitor combination therapies will launch, the first of which will be GlaxoSmithKline's Tafinlar/Mekinist, in 2014, in the United States and Europe. All BRAF/MEK inhibitor combination therapies will compete for market share in the unresectable/metastatic BRAF V600-mutation-positive patient population, with sales of this drug class accounting for one-fifth of the total market in 2022.

The report also finds that, despite the anticipated launch of several novel premium-priced therapies during the 2012-2022 forecast period, Yervoy will remain the sales leader through 2022 due to the agent's high price, its anticipated line-extension into the adjuvant setting and its anticipated first-line use in combination with nivolumab for unresectable/metastatic disease.

"When considering the melanoma clinical development pipeline, interviewed thought leaders are most excited about the immune checkpoint inhibitors," said Decision Resources Senior Business Insights Analyst, Karen Pomeranz, Ph.D. "We forecast that nivolumab and MK-3475 will launch for treatment of melanoma in all markets under study, attaining their highest sales in the first-line unresectable/metastatic setting. In 2022, nivolumab and MK-3475 will earn overall major market sales of nearly $1.1 billion."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Novel Oral Anticoagulants Will Continue to Drive Growth in the Atrial Fibrillation Drug Market
2. CPhI Japan 2014: Japanese Market to Continue to Dominate Global Pharma
3. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
4. Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%;
5. Widespread Acceptance and Use of Accurays Technologies Continue to Grow
6. ResMed Receives Injunctions against APEX and BMC in Germany, Continues Enforcement of Patents in Europe
7. STAAR Surgical Reports Continued Momentum During Third Quarter
8. Grant from Smith & Nephew Helps Continue Educational Activities for Podiatric Surgeons
9. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
10. Chronic Use of Prescription Painkillers Continues Following Bariatric Surgery
11. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016   BIOTRONIK will be exhibiting ... beyond the implant at the Heart Rhythm Society,s 37 ... San Francisco . "Physicians ... quality of patient care and satisfaction possible. Part of ... and every tomorrow," said Marlou Janssen , President, ...
(Date:5/3/2016)... , May 3, 2016  Specialty Silicone ... tool that shows how a cleanroom works. The ... discussions about science and technology. ... "As a technology company, SSF enthusiastically supports the ... help educators foster the next generation of innovators. ...
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 ... of death across the United States and account for one death every four minutes. ... or are permanently disabled. HCR ManorCare is launching a video series called “Your Brain,” ...
(Date:5/3/2016)... ... 2016 , ... Ogawa World USA introduced the first of its kind ... Smart Application. The Smart 3D combines the best in technological advancement, design, and massage ... and specialized massage program, each user has a tailored experience unparalleled by any other ...
(Date:5/3/2016)... ... May 03, 2016 , ... Intrigma, the leading provider ... Health is expanding its use of Intrigma’s cloud-based physician scheduling solution, Efficient Scheduler ... of concept. The Portland, Oregon based health system conducted a one-year pilot of ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... (IT) solutions and digital consulting services to the federal government, has been awarded ... Delivery / Indefinite Quantity (ID/IQ) contract in support of the U.S. Army Program ...
(Date:5/3/2016)... ... May 03, 2016 , ... Huntington Beach orthopedic ... of surgical procedure that can be used to diagnose and treat joint problems. During ... inserted. These instruments include a special lighting system and lens that illuminate and magnify ...
Breaking Medicine News(10 mins):